KYMERA THERAPEUTICS INC (KYMR) Fundamental Analysis & Valuation

NASDAQ:KYMR • US5015751044

Current stock price

86.14 USD
-1.03 (-1.18%)
Last:

This KYMR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. KYMR Profitability Analysis

1.1 Basic Checks

  • In the past year KYMR has reported negative net income.
  • KYMR had a negative operating cash flow in the past year.
  • KYMR had negative earnings in each of the past 5 years.
  • KYMR had a negative operating cash flow in each of the past 5 years.
KYMR Yearly Net Income VS EBIT VS OCF VS FCFKYMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -17.86%, KYMR is in the better half of the industry, outperforming 76.36% of the companies in the same industry.
  • KYMR has a better Return On Equity (-19.71%) than 81.98% of its industry peers.
Industry RankSector Rank
ROA -17.86%
ROE -19.71%
ROIC N/A
ROA(3y)-22.09%
ROA(5y)-21.7%
ROE(3y)-27.9%
ROE(5y)-27.42%
ROIC(3y)N/A
ROIC(5y)N/A
KYMR Yearly ROA, ROE, ROICKYMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • KYMR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYMR Yearly Profit, Operating, Gross MarginsKYMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. KYMR Health Analysis

2.1 Basic Checks

  • KYMR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KYMR has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for KYMR has been increased compared to 5 years ago.
  • KYMR has a better debt/assets ratio than last year.
KYMR Yearly Shares OutstandingKYMR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
KYMR Yearly Total Debt VS Total AssetsKYMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 25.23 indicates that KYMR is not in any danger for bankruptcy at the moment.
  • KYMR has a Altman-Z score of 25.23. This is amongst the best in the industry. KYMR outperforms 90.50% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that KYMR is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.00, KYMR perfoms like the industry average, outperforming 50.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.23
ROIC/WACCN/A
WACC9.55%
KYMR Yearly LT Debt VS Equity VS FCFKYMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • KYMR has a Current Ratio of 10.47. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
  • KYMR has a better Current ratio (10.47) than 81.40% of its industry peers.
  • KYMR has a Quick Ratio of 10.47. This indicates that KYMR is financially healthy and has no problem in meeting its short term obligations.
  • KYMR's Quick ratio of 10.47 is amongst the best of the industry. KYMR outperforms 81.40% of its industry peers.
Industry RankSector Rank
Current Ratio 10.47
Quick Ratio 10.47
KYMR Yearly Current Assets VS Current LiabilitesKYMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. KYMR Growth Analysis

3.1 Past

  • KYMR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.90%.
  • The Revenue for KYMR has decreased by -16.70% in the past year. This is quite bad
  • KYMR shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.87% yearly.
EPS 1Y (TTM)-26.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.23%
Revenue 1Y (TTM)-16.7%
Revenue growth 3Y-5.75%
Revenue growth 5Y2.87%
Sales Q2Q%-61.17%

3.2 Future

  • KYMR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.48% yearly.
  • KYMR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.82% yearly.
EPS Next Y-4.76%
EPS Next 2Y-5.01%
EPS Next 3Y-6.63%
EPS Next 5Y-4.48%
Revenue Next Year-23.17%
Revenue Next 2Y-8.84%
Revenue Next 3Y-9.99%
Revenue Next 5Y16.82%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KYMR Yearly Revenue VS EstimatesKYMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
KYMR Yearly EPS VS EstimatesKYMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. KYMR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KYMR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KYMR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYMR Price Earnings VS Forward Price EarningsKYMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYMR Per share dataKYMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • KYMR's earnings are expected to decrease with -6.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.01%
EPS Next 3Y-6.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. KYMR Dividend Analysis

5.1 Amount

  • No dividends for KYMR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KYMR Fundamentals: All Metrics, Ratios and Statistics

KYMERA THERAPEUTICS INC

NASDAQ:KYMR (4/24/2026, 2:04:53 PM)

86.14

-1.03 (-1.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)04-30
Inst Owners110.04%
Inst Owner Change0.01%
Ins Owners1.28%
Ins Owner Change0.21%
Market Cap7.03B
Revenue(TTM)39.21M
Net Income(TTM)-311.35M
Analysts86.21
Price Target121.23 (40.74%)
Short Float %13.09%
Short Ratio13.93
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.03%
Min EPS beat(2)-19.43%
Max EPS beat(2)-14.63%
EPS beat(4)1
Avg EPS beat(4)-9.2%
Min EPS beat(4)-19.43%
Max EPS beat(4)12.26%
EPS beat(8)4
Avg EPS beat(8)-1.36%
EPS beat(12)5
Avg EPS beat(12)-1.12%
EPS beat(16)6
Avg EPS beat(16)-1.88%
Revenue beat(2)0
Avg Revenue beat(2)-83.5%
Min Revenue beat(2)-85.7%
Max Revenue beat(2)-81.3%
Revenue beat(4)1
Avg Revenue beat(4)-26.38%
Min Revenue beat(4)-85.7%
Max Revenue beat(4)113.36%
Revenue beat(8)2
Avg Revenue beat(8)-16.85%
Revenue beat(12)4
Avg Revenue beat(12)-17.76%
Revenue beat(16)4
Avg Revenue beat(16)-21.38%
PT rev (1m)5.62%
PT rev (3m)7.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.63%
EPS NY rev (1m)-2%
EPS NY rev (3m)-1.64%
Revenue NQ rev (1m)3.01%
Revenue NQ rev (3m)-13.98%
Revenue NY rev (1m)-1.11%
Revenue NY rev (3m)-12.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 179.35
P/FCF N/A
P/OCF N/A
P/B 4.45
P/tB 4.45
EV/EBITDA N/A
EPS(TTM)-3.68
EYN/A
EPS(NY)-3.86
Fwd EYN/A
FCF(TTM)-2.87
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS0.48
BVpS19.35
TBVpS19.35
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -17.86%
ROE -19.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.09%
ROA(5y)-21.7%
ROE(3y)-27.9%
ROE(5y)-27.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.43%
Cap/Sales 3.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.47
Quick Ratio 10.47
Altman-Z 25.23
F-Score4
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)386.24%
Cap/Depr(5y)264.14%
Cap/Sales(3y)24.95%
Cap/Sales(5y)16.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.23%
EPS Next Y-4.76%
EPS Next 2Y-5.01%
EPS Next 3Y-6.63%
EPS Next 5Y-4.48%
Revenue 1Y (TTM)-16.7%
Revenue growth 3Y-5.75%
Revenue growth 5Y2.87%
Sales Q2Q%-61.17%
Revenue Next Year-23.17%
Revenue Next 2Y-8.84%
Revenue Next 3Y-9.99%
Revenue Next 5Y16.82%
EBIT growth 1Y-34.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.25%
EBIT Next 3Y-6.45%
EBIT Next 5YN/A
FCF growth 1Y-13.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.74%
OCF growth 3YN/A
OCF growth 5YN/A

KYMERA THERAPEUTICS INC / KYMR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KYMERA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to KYMR.


What is the valuation status of KYMERA THERAPEUTICS INC (KYMR) stock?

ChartMill assigns a valuation rating of 0 / 10 to KYMERA THERAPEUTICS INC (KYMR). This can be considered as Overvalued.


What is the profitability of KYMR stock?

KYMERA THERAPEUTICS INC (KYMR) has a profitability rating of 1 / 10.